Check-Cap (NASDAQ:CHEK) Receives New Coverage from Analysts at assumed coverage on shares of Check-Cap (NASDAQ:CHEKFree Report) in a research report sent to investors on Friday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of CHEK stock traded down $0.05 on Friday, reaching $2.19. 14,010 shares of the company were exchanged, compared to its average volume of 16,423. The company has a 50-day moving average of $2.28 and a 200-day moving average of $2.45. The company has a market cap of $12.78 million, a price-to-earnings ratio of -0.72 and a beta of 0.45. Check-Cap has a one year low of $1.41 and a one year high of $4.63.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Recommended Stories

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with's FREE daily email newsletter.